Analysts Set Maze Therapeutics, Inc. (NASDAQ:MAZE) PT at $66.00

Shares of Maze Therapeutics, Inc. (NASDAQ:MAZE) have been given a consensus recommendation of “Buy” by the twelve brokerages that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, eight have issued a buy rating and three have assigned a strong buy rating to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $66.00.

A number of analysts recently weighed in on the stock. Wall Street Zen cut shares of Maze Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of Maze Therapeutics in a research note on Wednesday, June 24th. BTIG Research restated a “buy” rating and issued a $46.00 target price on shares of Maze Therapeutics in a research report on Wednesday, August 12th. Finally, TD Cowen upgraded shares of Maze Therapeutics to a “strong-buy” rating in a research note on Monday, August 24th.

Maze Therapeutics Trading Up 1.0%

Shares of NASDAQ MAZE opened at $24.82 on Friday. The company has a market cap of $1.38 billion, a price-to-earnings ratio of -9.85 and a beta of 2.17. Maze Therapeutics has a 12-month low of $20.00 and a 12-month high of $53.65. The company has a current ratio of 18.31, a quick ratio of 18.31 and a debt-to-equity ratio of 0.09. The stock’s 50 day simple moving average is $28.33 and its 200 day simple moving average is $30.50.

Maze Therapeutics (NASDAQ:MAZE) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.76) EPS for the quarter, hitting analysts’ consensus estimates of ($0.76). Equities research analysts expect that Maze Therapeutics will post -2.72 EPS for the current year.

Insiders Place Their Bets

In other Maze Therapeutics news, insider Courtney Phillips sold 2,012 shares of the business’s stock in a transaction on Thursday, September 3rd. The stock was sold at an average price of $26.01, for a total transaction of $52,332.12. Following the completion of the transaction, the insider owned 7,007 shares in the company, valued at approximately $182,252.07. The trade was a 22.31% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CMO Harold Bernstein sold 9,705 shares of Maze Therapeutics stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $26.22, for a total transaction of $254,465.10. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 219,317 shares of company stock valued at $5,989,040 in the last quarter. 5.30% of the stock is owned by insiders.

Institutional Trading of Maze Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in shares of Maze Therapeutics in the 1st quarter worth approximately $57,000. Goldman Sachs Group Inc. bought a new position in shares of Maze Therapeutics in the first quarter valued at approximately $145,000. Rhumbline Advisers acquired a new position in shares of Maze Therapeutics during the first quarter valued at approximately $80,000. Geode Capital Management LLC increased its stake in shares of Maze Therapeutics by 8.8% during the second quarter. Geode Capital Management LLC now owns 231,237 shares of the company’s stock valued at $2,838,000 after acquiring an additional 18,773 shares during the period. Finally, Legal & General Group Plc raised its holdings in Maze Therapeutics by 387.0% during the second quarter. Legal & General Group Plc now owns 4,242 shares of the company’s stock worth $52,000 after purchasing an additional 3,371 shares in the last quarter.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.